{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028174","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.655810+00:00","generated_at":"2026-06-22T08:40:21.728375+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ardelyx Q3 2022 net loss $22.9M; IBSRELA sales $4.9M; expects $35M Japan milestone","bullets":["Net loss of $22.9M ($0.14 per share) versus $43.6M ($0.42) in Q3 2021; narrowed 47%.","IBSRELA net product sales of $4.9M for Q3 2022, six months into launch.","Cash, equivalents and investments $90.6M at Sept 30, 2022, down from $116.7M at Dec 31, 2021.","Kyowa Kirin submitted tenapanor NDA in Japan; Ardelyx expects aggregate $35M milestones in Q4 2022.","FDA Advisory Committee for XPHOZAH (tenapanor) scheduled for November 16, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028174","json":"https://secwatch.observer/filing/0001628280-22-028174.json","markdown":"https://secwatch.observer/filing/0001628280-22-028174.md","text":"https://secwatch.observer/filing/0001628280-22-028174.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022028174/0001628280-22-028174-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022028174/ardx-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:40:21.728375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bab116051028eb6a941ae694f05e8165978a46a5","claim":"ARDELYX, INC. reported the fiscal quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022 was $22.9 million, or $(0.14) per share, EPS $(0.14) per share.","evidence_excerpt":"On November 3, 2022, Ardelyx, Inc. (the “Company”) announced its financial results for the fiscal quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828022028174/0001628280-22-028174-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the quarter ended September 30, 2022 was $22.9 million, or $(0.14) per share"},{"label":"EPS","value":"$(0.14) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}